TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed. Our target-first, rational approach to molecular glue discovery lets us consider a wide-range of therapeutic applications for our products. Our initial focus on targeted protein degradation is driven by our desire to discover and develop groundbreaking new cancer medicines. TRIANA Biomedicines is headquartered in Waltham, Massachusetts, and has established internal laboratory work as well as key collaborations with academia and industry partners.
Something looks off?